Organogenesis Holdings Inc (ORGO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ORGO
Organogenesis Holdings Inc
$2.44
+1.24%
HEALTHCARE · Cap: $317.74M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 791255% more annual revenue ($4.46T vs $564.17M). ORGO leads profitability with a 6.6% profit margin vs 2.5%. ORGO trades at a lower P/E of 16.5x. ORGO earns a higher WallStSmart Score of 67/100 (B-).
ORGO
Strong Buy67
out of 100
Grade: B-
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.7%
Fair Value
$7.02
Current Price
$2.44
$4.58 discount
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
6.6% margin — thin
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 78.1% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
ORGO profiles as a hypergrowth stock while TAK is a value play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.39 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 60/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?